Impact of high-dose, chemically modified sulfamidase on pathology in a murine model of MPS IIIA

Tina Rozaklis, Helen Beard, Sofia Hassiotis, Antony R. Garcia, Matthew Tonini, Amanda Luck, Jing Pan, Justin C. Lamsa, John J. Hopwood, Kim M. Hemsley

Research output: Contribution to journalArticlepeer-review

41 Citations (Scopus)


Mucopolysaccharidosis type IIIA (MPS IIIA) is a neurodegenerative lysosomal storage disorder that results from a deficiency of sulfamidase (N-sulfoglucosamine sulfohydrolase), with consequential accumulation of its substrate, partially degraded heparan sulfate. Conventional doses (e.g. 1. mg/kg) of intravenously delivered recombinant human sulfamidase (rhSGSH) do not improve neuropathology in MPS IIIA mice due to an inability to traverse the blood-brain barrier; however high-dose treatment or administration of enzyme that has been chemically modified to remove mannose-6-phosphate glycans has been shown to reduce neuropathology in related animal models. We have combined these approaches to evaluate the ability of 1, 5, 10 or 20. mg/kg of similarly chemically modified or unmodified rhSGSH to reduce neuropathology following repeated intravenous delivery to adult MPS IIIA mice. rhSGSH was detected in brain homogenates from mice treated with all doses of modified rhSGSH and those receiving the two higher doses of unmodified rhSGSH, albeit at significantly lower levels. Immunohistochemically, rhSGSH visualized in the brain was localized to the endothelium, meninges and choroid plexus, with no convincing punctate intra-neuronal staining seen. This presumably underlies the failure of the treatment to reduce the relative level of a heparan sulfate-derived oligosaccharide (GlcNS-UA), or secondarily stored substrates that accumulate in MPS IIIA brain cells. However, modification of rhSGSH significantly increased its effectiveness in degrading GlcNS-UA in non-CNS tissues, potentially as a result of its reduced plasma clearance. If this observation is generally applicable, chemical modification may permit the use of significantly lower doses of lysosomal enzymes in patients currently receiving intravenous enzyme replacement therapy.

Original languageEnglish
Pages (from-to)123-130
Number of pages8
JournalExperimental Neurology
Issue number1
Publication statusPublished - Jul 2011
Externally publishedYes


  • Brain
  • Enzyme replacement therapy
  • Mouse
  • Mucopolysaccharidosis
  • Sanfilippo


Dive into the research topics of 'Impact of high-dose, chemically modified sulfamidase on pathology in a murine model of MPS IIIA'. Together they form a unique fingerprint.

Cite this